Pharmacological interventions for prevention of depression in high risk conditions: Systematic review and meta-analysis.

[1]  M. T. Madsen,et al.  The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial. , 2019, Journal of psychiatric research.

[2]  P. Sandercock,et al.  Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial , 2019, Lancet.

[3]  D. Rubinow,et al.  Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial , 2018, JAMA psychiatry.

[4]  L. Howard,et al.  Antidepressants for preventing postnatal depression. , 2018, The Cochrane database of systematic reviews.

[5]  B. Horne,et al.  The association of depression at any time to the risk of death following coronary artery disease diagnosis , 2017, European heart journal. Quality of care & clinical outcomes.

[6]  A. Nardi,et al.  Omega-3 supplementation from pregnancy to postpartum to prevent depressive symptoms: a randomized placebo-controlled trial , 2017, BMC Pregnancy and Childbirth.

[7]  R. Robinson,et al.  Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury: A Randomized Clinical Trial. , 2016, JAMA psychiatry.

[8]  G. Andersen,et al.  Early Antidepressant Treatment and All-Cause 30-Day Mortality in Patients with Ischemic Stroke , 2015, Cerebrovascular Diseases.

[9]  P. Cuijpers,et al.  Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. , 2015, The lancet. Psychiatry.

[10]  C. Pariante,et al.  Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial , 2014, Biological Psychiatry.

[11]  J. Singer,et al.  Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial , 2014, HIV clinical trials.

[12]  P. Cuijpers,et al.  Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions. , 2014, International journal of epidemiology.

[13]  C. Epperson,et al.  Preventing postpartum depression: a meta-analytic review. , 2013, Clinical psychology review.

[14]  T. Vos,et al.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet.

[15]  R. Teasell,et al.  Prevention of poststroke depression: does prophylactic pharmacotherapy work? , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[16]  Brendan Miller,et al.  Dietary supplements for preventing postnatal depression. , 2013, The Cochrane database of systematic reviews.

[17]  Awad Al-omari,et al.  Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline: A Systematic Review and Meta-Analysis , 2013 .

[18]  H. Sayles,et al.  Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. , 2013, JAMA otolaryngology-- head & neck surgery.

[19]  Jin-Hua Zhang,et al.  Prophylactic Effects of Duloxetine on Post-Stroke Depression Symptoms: An Open Single-Blind Trial , 2013, European Neurology.

[20]  G. Carrà,et al.  Depression after Stroke and Risk of Mortality: A Systematic Review and Meta-Analysis , 2013, Stroke research and treatment.

[21]  C. Wolfe,et al.  Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis , 2013, British Journal of Psychiatry.

[22]  A. Heinz,et al.  Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease , 2012, Annals of Internal Medicine.

[23]  P. Cuijpers,et al.  Preventing depression: a global priority. , 2012, JAMA.

[24]  R. D. de Knegt,et al.  Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon‐alfa‐2a and ribavirin for chronic hepatitis C , 2011, Alimentary pharmacology & therapeutics.

[25]  Joel Rennó,et al.  Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women , 2011, Archives of Women's Mental Health.

[26]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[27]  Chen-Long Wu,et al.  Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial , 2011, International clinical psychopharmacology.

[28]  Joan Costa,et al.  Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. , 2011, The Journal of clinical psychiatry.

[29]  F. Chollet,et al.  Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial , 2011, The Lancet Neurology.

[30]  G. Ferns,et al.  Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trial , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[31]  B. Felker,et al.  Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. , 2010, Psychosomatics.

[32]  N. Kar,et al.  Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. , 2010, The British journal of psychiatry : the journal of mental science.

[33]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[34]  Andreas Stang,et al.  Common problems related to the use of number needed to treat. , 2010, Journal of clinical epidemiology.

[35]  S. Pol,et al.  246 ASSESSMENT OF PAROXETINE IN THE PREVENTION OF DEPRESSION IN PATIENTS WITH CHRONIC HEPATITIS C TREATED BY PEG-INTERFERON-RIBAVIRIN.: A DOUBLE-BLINDED, RANDOMIZED STUDY. ANRS HC18 PAROPEG , 2010 .

[36]  P. Cuijpers,et al.  Prevention of major depression. , 2010, Annual review of clinical psychology.

[37]  T. Novack,et al.  Impact of early administration of sertraline on depressive symptoms in the first year after traumatic brain injury. , 2009, Journal of neurotrauma.

[38]  B. Yawn,et al.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. , 2009 .

[39]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[40]  P. Cuijpers,et al.  Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. , 2008, The American journal of psychiatry.

[41]  S. Small,et al.  Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. , 2008, JAMA.

[42]  W. Burke,et al.  A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. , 2008, Archives of otolaryngology--head & neck surgery.

[43]  P. Hauser,et al.  A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. , 2007, Journal of affective disorders.

[44]  Donna Bergen.  Neurological Disorders: Public Health Challenges , 2007 .

[45]  J. Zajecka,et al.  Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C , 2007, Alimentary pharmacology & therapeutics.

[46]  G. Hankey,et al.  Preventing depression after stroke: Results from a randomized placebo-controlled trial. , 2006, The Journal of clinical psychiatry.

[47]  D. Kupfer.  The pharmacological management of depression , 2005, Dialogues in clinical neuroscience.

[48]  M. Aguilar,et al.  Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. , 2005, The Cochrane database of systematic reviews.

[49]  N. Niedermaier,et al.  Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. , 2004, The Journal of clinical psychiatry.

[50]  B. Hanusa,et al.  Prevention of postpartum depression: a pilot randomized clinical trial. , 2004, The American journal of psychiatry.

[51]  Helen Lapsley,et al.  Utilising survey data to inform public policy: Comparison of the cost-effectiveness of treatment of ten mental disorders , 2004, British Journal of Psychiatry.

[52]  M H Trivedi,et al.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation , 2004, Psychological Medicine.

[53]  P. Bech,et al.  A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. , 2003, Psychosomatics.

[54]  R. Robinson,et al.  Preventing Poststroke Depression: A 12-Week Double-Blind Randomized Treatment Trial and 21-Month Follow-up , 2002, The Journal of nervous and mental disease.

[55]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[56]  T. Brugha,et al.  SCAN. Schedules for Clinical Assessment in Neuropsychiatry. , 1990, Archives of general psychiatry.

[57]  J. Cox,et al.  Detection of Postnatal Depression , 1987, British Journal of Psychiatry.

[58]  A. Zigmond,et al.  The Hospital Anxiety and Depression Scale , 1983, Acta psychiatrica Scandinavica.

[59]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[60]  E. Robins,et al.  Research diagnostic criteria: rationale and reliability. , 1978, Archives of general psychiatry.

[61]  L. Radloff.  The CES-D Scale , 1977 .

[62]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[63]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[64]  O. Nielsen,et al.  Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). , 2012, Journal of psychosomatic research.

[65]  S. Spence,et al.  Preventing adolescent depression: an evaluation of the problem solving for life program. , 2003, Journal of consulting and clinical psychology.

[66]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[67]  B. Hanusa,et al.  Prevention of recurrent postpartum depression: a randomized clinical trial. , 2001, The Journal of clinical psychiatry.

[68]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.